Dr. Julie Decock received her Master of Science (MSc) in Biomedical Sciences from the Free University of Brussels (VUB, Belgium) and completed her Doctor of Philosophy (PhD) in Medical Sciences at the Catholic University of Leuven, KU Leuven, Belgium. Her doctoral research focused on the cancer degradome, the repertoire of proteases in the tumor microenvironment that contribute to shaping the extracellular environment and modulating pericellular signaling, thereby affecting tumor progression and clinical outcome.
She joined QBRI in 2013 and established a research program in the areas of tumor antigen discovery and tumor immunity, two key research areas that can help accelerate breast cancer research and advance the development of new treatments. Currently, her research focuses on cancer testis antigens, a group of tumor associated antigens that play pivotal roles in tumorigenesis and progression, and display high tumor specificity with minimal on- and off-target side effects. Her efforts have demonstrated that cancer testis antigens not only play important roles in multiple cancer hallmarks but can also serve as tumor specific molecular targets and modulators of anti-tumor immunity, offering diverse opportunities for anti-cancer targeting.
Dr. Decock is currently a scientist at the Translational Cancer and Immunity Center, Qatar Biomedical Research Institute (QBRI), and a joint Assistant Professor position at HBKU’s College of Health and Life Sciences (CHLS).
Qatar Biomedical Research Institute (QBRI), Qatar.2016 - present
College of Health and Life Sciences (CHLS), Hamad Bin Khalifa University (HBKU), Doha, Qatar.2016 - present
Cancer Research Center, Qatar Biomedical Research Institute (QBRI), Qatar.2013 - 2016
School of Biological Sciences, Faculty of Science, University of East Anglia (UEA), UK.2008 - 2013
Faculty of Medicine, Catholic University of Leuven (KULeuven), Belgium2008
Free University of Brussels (VUB), Belgium2002
Al-Siddiqi HH, Butler AE, Decock J, Mohamed-Ali V, Al-Ejeh F. Prognostic tools and candidate drugs based on plasma proteomics of patients with severe COVID-19 complications. Nat Commun. 2022;13(1):946. https://doi.org/10.1038/s41467-022-28639-4.2022
Targeting of lactate dehydrogenase C dysregulates the cell cycle and sensitizes breast cancer cells to DNA damage response targeted therapy. Mol Oncol. 2022 Feb;16(4):885-903. doi: 10.1002/1878-0261.13024.2022
Cancer testis antigen PRAME: An anti-cancer target with immunomodulatory potential. J Cell Mol Med. 2021;25(22):10376-103888. doi: 10.1111/jcmm.16967.2021
Immune checkpoint inhibitors in triple negative breast cancer treatment: promising future prospects. Front Oncol. 2021;10:600573. doi:10.3389/fonc.2020.600573.2021
Ancestry-associated transcriptomic profiles of breast cancer in patients of African, Arab and European ancestry. NPJ Breast Cancer. 2021 Feb 8;7(1):10. doi: 10.1038/s41523-021-00215-x.2021
Immune checkpoints in the tumor microenvironment. Semin Cancer Biol. 2020;65:1-12. doi: 10.1016/j.semcancer.2019.06.021.2020
Lactate Metabolism and Immune Modulation in Breast Cancer: A Focused Review on Triple Negative Breast Tumors. Front. Oncol., doi:10.3389/fonc.2020.598626.2020
Identification of two HLA-A*0201 immunogenic epitopes of lactate dehydrogenase C (LDHC): potential novel targets for cancer immunotherapy. Cancer Immunol Immunother. 2020 Jan 13. doi: 10.1007/s00262-020-02480-4.2020
The obesity paradox in cancer, tumor immunology and immunotherapy: Focus on triple negative breast cancer. Front. Immunol. 10:1940. doi: 10.3389/fimmu.2019.01940. Review.2019
Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME? Cancers (Basel). 2019 Jul 15; 11(7). Review.2019
PRAME promotes epithelial-to-mesenchymal transition in triple negative breast cancer. J Transl Med. 17(1):9. doi: 10.1186/s12967-018-1757-3.2019
NY-ESO-1 based immunotherapy of cancer: current perspectives. Front. Immunol. 9:947. doi: 10.3389/fimmu.2018.00947. Review.2018
Complete list of publications https://www.ncbi.nlm.nih.gov/myncbi/julie.decock.1/bibliography/public/